C12N 2710/20034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/20034 (Use of virus or viral component as vaccine) appears on 475 US grants and 853 published applications in this corpus.
Search patents in C12N- Granted patents
- 475
- Published applications
- 853
- Assignees
- 384
- Inventors
- 1,382
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 6 | 0 |
| 1999 | 7 | 0 |
| 2000 | 4 | 0 |
| 2001 | 7 | 4 |
| 2002 | 6 | 9 |
| 2003 | 9 | 9 |
| 2004 | 6 | 27 |
| 2005 | 6 | 15 |
| 2006 | 5 | 19 |
| 2007 | 15 | 23 |
| 2008 | 11 | 26 |
| 2009 | 10 | 18 |
| 2010 | 12 | 39 |
| 2011 | 8 | 22 |
| 2012 | 14 | 27 |
| 2013 | 7 | 20 |
| 2014 | 16 | 20 |
| 2015 | 18 | 34 |
| 2016 | 22 | 41 |
| 2017 | 33 | 39 |
| 2018 | 32 | 43 |
| 2019 | 25 | 44 |
| 2020 | 26 | 36 |
| 2021 | 30 | 59 |
| 2022 | 36 | 52 |
| 2023 | 31 | 71 |
| 2024 | 25 | 71 |
| 2025 | 33 | 58 |
| 2026 | 9 | 27 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Cell capable of activating immune system, and pharmaceutical composition containing said cell11 Aug 2026US 12,703,867 B2Riken
- Thermostable lipid nanoparticle and methods of use thereof4 Aug 2026US 12,697,308 B2Merck Sharp & Dohme Corp.
- HPV vaccine7 Jul 2026US 12,673,103 B2Merck Sharp & Dohme Corp.
- Methods for treating HPV-associated diseases14 Apr 2026US 12,599,656 B2
- A novel non-stoichiometric multi-element adjuvant (nsma) and composition thereof8 Oct 2026US 2026/0306624 A1Magvitae Innovations Inc
- Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes27 Aug 2026US 2026/0248753 A1PDS Biotechnology Corporation
- A Fusion Protein and a Particulate Antigen Containing the Same27 Aug 2026US 2026/0250328 A1Xiamen Innovax Biotech Co., Ltd.
- A therapeutic hpv vaccine based on validated target epitopes20 Aug 2026US 2026/0240974 A1Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
- Validated hpv16-derived stimulation peptides20 Aug 2026US 2026/0240975 A1Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
Most cited
By later US patents
- Adjuvant systems and vaccines92US 7,357,936 B1SmithKline Beecham Biologicals s.a. · 2008
- Sexually transmitted disease vaccines86US 10,493,143 B2ModernaTX, Inc. · 2019
- Antigen delivery compositions and methods of use85US 7,303,881 B2PDS Biotechnology Corporation · 2007
- Process for purifying human papillomavirus virus-like particles53US 6,602,697 B1Merck & Co., Inc. · 2003
- Chimeric papillomavirus-like particles49US 5,618,536 AThe United States of America as represented by the Department of Health and Human Services · 1997